StockGlow

Definium Therapeutics, Inc. (DFTX)

Develops drugs to treat anxiety, depression, and autism spectrum disorder.

$41.96-0.02%Healthcare
Compare DFTX with
StockGlow Score
92
Bullish
BearishBullish
1 year ago+397.2%

The outlook

Analysts rate DFTX a Strong Buy, with the average price target sitting about 43% above current levels. The stock is trading above both its 50- and 200-day moving averages and sits in the upper portion of its 52-week range, reflecting sustained upward momentum over recent months.

What’s behind the score

Analyst consensusStrong Buy — 1.3 avg of 16 analysts
Price trendAbove its 50- & 200-day averages
52-week range82% of the way from its 52-week low to high
Price targetAvg target +43% vs current price

Analyst price target

~12-month · 16 analysts
$60.00average target+43.0% vs now
Now $41.96
Low $50.00High $74.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$5.57B
52-wk high
$49.20
52-wk low
$7.96
50-day avg
$33.52
200-day avg
$20.50
Trailing P/E
—

Similar stocks

CMPSCOMPASS Pathways plc$10.85-3.73%HELPCybin D/B/A Helus Pharma$7.60-1.30%AACGATA Creativity Global$0.97+5.43%CLOVClover Health Investments, Corp.$4.34+1.52%MVISMicroVision, Inc.$0.25-2.45%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy